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Abstract
Background: Ophthalmic artery chemosurgery (OAC) for retinoblastoma was introduced by us 5 years ago for advanced
intraocular retinoblastoma. Because the success was higher than with existing alternatives and systemic side effects limited
we have now treated less advanced intraocular retinoblastoma (Reese-Ellsworth (RE) I-III and International Classification
Retinoblastoma (ICRB) B and C).
Methodology/Principal Findings: Retrospective review of 5 year experience in eyes with Reese Ellsworth (Table 1) I (7 eyes),
II (6 eyes) or III (6 eyes) and/or International Classification (Table 2) B (19 eyes) and C (11 eyes) treated with OAC (melphalan
with or without topotecan) introduced directly into the ophthalmic artery. Patient survival was 100%. Ocular event-free
survival was 100% for Reese-Ellsworth Groups I, II and III (and 96% for ICRB B and C) at a median of 16 months follow-up.
One ICRB Group C (Reese-Ellsworth Vb) eye could not be treated on the second attempt for technical reasons and was
therefore enucleated. No patient required a port and only one patient required transfusion of blood products. The
electroretinogram (ERG) was unchanged or improved in 14/19 eyes.
Conclusions/Significance: Ophthalmic artery chemosurgery for retinoblastoma that was Reese-Ellsworth I, II and III (or
International Classification B or C) was associated with high success (100% of treatable eyes were retained) and limited
toxicity with results that equal or exceed conventional therapy with less toxicity.
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Introduction
Ophthalmic artery chemosurgery (OAC) for retinoblastoma was
first performed 5 years ago by us as in the hope of saving eyes with
extensive intraocular retinoblastoma scheduled for enucleation [1].
It has now been performed successfully in 26 countries worldwide
and more than 20 peer-reviewed publications have demonstrated
that the majority of eyes so treated can avoid enucleation or
radiation. This has been accomplished with minimal systemic
toxicity, in as few as one cycle of a single drug and with acceptable
local ophthalmic toxicity.
The first attempt to deliver high doses to the eye while
minimizing systemic exposure was performed by Reese more than
50 years ago with a very different rationale in mind [2]. Reese
delivered intra-arterial Triethylene Melanamine (TEM) (a nitro-
gen mustard derivative) via direct carotid artery puncture on the
side to be treated in an attempt to lower the dose of therapeutic
radiation used to treat retinoblastoma. Intrarterial TEM allowed
him to lower the dose by 50% (from 15,000cGy to 7,500cGy) and
he wrote ‘‘it is amazing to see the clinical regression of a lesion
following employment of x-ray together with one injection of
TEM by way of the carotid artery’’ [2].
Investigators from Japan then began a different form of intra-
arterial chemotherapy in retinoblastoma for a very different
reason. They developed a balloon catheter that was introduced via
the femoral artery and allowed for occlusion of the internal carotid
artery on the side to be treated with rapid infusion of drugs (usually
single agent melphalan) proximal to the balloon-hence they called
it ‘‘selective intrarterial chemotherapy’’ [3]. They were not trying
to lower the dose of radiation. In Japan clinicians faced a cultural
challenge. Families of children with unilateral retinoblastoma (who
could be cured of disease with just an enucleation) refused curative
enucleation for cultural reasons. The physicians therefore decided
that they would treat eyes with everything possible in the hope of
salvaging a life by saving an eye-no matter what the ocular
consequences might be. They combined their intra-arterial
technique with external beam irradiation, hyperthermia, intravit-
real injection of chemotherapy and focal laser and/or cryotherapy
in an attempt to salvage the eye. Their recent report highlighted
their success in avoiding enucleation of advanced eyes and is
reassuring that no long term consequences (since 1986)-especially
second cancers-were observed [4].
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advancing a micro-catheter into the orifice of the ophthalmic
artery on the side to be treated (or both sides in the same session in
cases of bilateral retinoblastoma- ‘‘tandem therapy’’ [5]) after
introduction of the catheter via the femoral artery. In our initial
report we demonstrated that 7 of 9 eyes scheduled for enucleation
could be spared enucleation as a result of this new approach [1].
Since that first report three years ago many have reported the
success and complications of this technique in (very) advanced
eyes-usually scheduled for enucleation. The largest report to date
is from our center. Of 95 eyes treated over a four- year period 87
were advanced (Reese-Ellsworth (RE) Groups IV–V) and only 8
less advanced eyes were treated [6]. 100% of the eyes treated in
Miami were advanced (RE Vb or International Classification
(ICRB) Group D) [7]. Similarly 100% of the eyes treated in
Switzerland were advanced [8]. Of 17 eyes treated in Philadelphia
all but 2 were similarly advanced [9].
Because our systemic toxicity in treating children with advanced
intraocular retinoblastoma was limited (most frequently asymp-
tomatic Grade 3 neutropenia), we began treating less advanced
retinoblastoma and now report on the success and adverse events
in these patients.
Methods
We have previously described our technique of ophthalmic
artery chemosurgery that achieves super selective delivery of
chemotherapy in the eyes of children with retinoblastoma [1,3,10].
A 4-French arterial sheath is introduced into the femoral artery
(alternating sides with each successive treatment) under general
anesthesia and anticoagulation attained with intravenous heparin
(75I U/kg). Microcatheters are then passed into the ophthalmic
artery on the side to be treated using fluoroscopy and road-
mapping. Both flow-directed catheters (such as the Magic-Balt
Therapeutics, Montmorency, France) with outer diameters of 400
or 500 microns and guidewire-directed catheters (such as the
Excelsior SL 10 Stryker, Freemont CA) with an outer diameter of
570 microns have been used. The chemotherapy drugs are then
diluted with saline in a 30cc solution, injected in a pulsatile fashion
over 30 minutes. At the end of the procedure the catheter is
withdrawn, the femoral puncture site is compressed for hemostasis
and the child discharged the same day. Children had either RE
Groups I, II or III and/or ICRB B or C (Table 3). Although both
RE Groups I-III and ICRB Groups B and C are considered less
advanced groups each Group uses different criteria so the actual
number of cases in RE I-III are not the same as ICRB B and C. In
particular ICRB C include eyes with vitreous seeding while in RE,
by definition, no seeding is present in Groups I, II or III.
Examinations under anesthesia were performed every 3 or 4
weeks and included assessment of vision, motility and pupillary
responses before dilation (or anesthesia) and then after dilation
(under anesthesia) an ophthalmic exam including fundus photog-
raphy with the RetCam, ultrasound and retinal function
monitoring with our modified full electroretinogram protocol
performed (including photopic and scotopic responses) [11]. As in
earlier manuscripts we report 30-Hz flicker responses as a
surrogate for ERG responses. Changes in 30-Hz ERG amplitudes
of less than 25 mV were considered inconsequential. Fluorescein
angiograms were not done on a routine basis.
This study was performed with the approval of the Institutional
Review Board at Memorial Sloan-Kettering Cancer Center.
Written, informed consent (from parents) was obtained for all
participants in this study.
Results
The demographic data of the patient population are presented
in Table 3.
No patient developed metastatic disease and all patients are
alive. No second cancers have developed.
Catheterization was successful in all patients except one. This
patient was a 7 year-old girl with chromosome 13 deletion
syndrome classified as ICRB C and RE Vb. The tumor had
progressed despite 6 cycles of multi-agent systemic chemotherapy
elsewhere and though the first attempt was successful the second
treatment could not be done for technical reasons and the eye was
enucleated. The child is alive and well.
Ocular event-free survival (RE Group I, II and III) and patient
survival were 100% at a median follow-up from the last treatment
of 16 months (range 3–31 months). One Group C eye was
enucleated after canulation was technically impossible on the
second attempt. Fundus photographs of three eyes before and after
treatment with ophthalmic artery chemosurgery are seen in
Figure 1.
There were no seizures, strokes or hospitalizations after the
procedure and no significant systemic toxicities. No child has
required a port. Hematologic toxicity was graded by the standard
CTCAEv4 scheme. Of 68 infusions 46 (67%) were associated with
no hematologic toxicity. In 16 sessions grade III hematologic
toxicity developed, in 6 sessions Grade IV toxicity developed. This
Table 1. Reese-Ellsworth (RE) Classification Scheme.
Reese-Ellsworth (RE) Classification For Intraocular Retinoblastoma
GROUP I a. Solitary tumor, less than 4 disc diameters in size, at or behind the equator
b. Multiple tumors, none over 4 disc diameters in size, all at or behind the equator
GROUP II a. Solitary tumor, less than 4 to 10 disc diameters in size, at or behind the equator
b. Multiple tumors, none over 4 to 10 disc diameters in size, all at or behind the equator
GROUP III a. Any lesion anterior to the equator
b. Solitary tumors larger than 10 disc diameters behind the equator
GROUP IV a. Multiple tumors, some larger than 10 disc diameters
b. Any lesion extending anteriorly to the ora serrata
GROUP V a. Massive tumors involving over half the retina
b. Vitreous seeding
doi:10.1371/journal.pone.0034120.t001
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systemic chemotherapy 6 times) who developed Grade III ANC
twice, Grade IV once and Grade IV platelet toxicity once and
required hospitalization for febrile neutropenia.
Additional treatments were performed after intra-arterial
chemotherapy in 11 of the 19 RE Group I-III eyes. Eight eyes
(8/19; 42%) have not received additional treatments. Three eyes
received both local cryotherapy and laser ablation and 8 eyes
received laser ablation only. Regarding the ICRB Group B and C
eyes, 19 of the 26 retained eyes were treated with focal laser only
(15 eyes), cryotherapy only (1 eye), or both (3 eyes).
Compared with initial results, 30 Hz ERG responses as of the
most recent follow-up examination were unchanged in 7 patients,
improved by at least 25 mV in 7 patients, and decreased by at least
25 mV in 5 patients. Of those ERGs that deteriorated 4 remained
in our ‘‘Good’’ category (.75 mV), which is considered a normal
30 Hz ERG response amplitude in most clinical laboratories.
Discussion
Although ophthalmic artery chemosurgery was first performed
just 5 years ago for childhood retinoblastoma it has rapidly
become an accepted modality that saves eyes with advanced
retinoblastoma that would otherwise have been enucleated. Unlike
systemic chemotherapy single agent intrarterial chemotherapy can
be curative alone. Because we had such success (and minimal
toxicity) in advanced eyes we have now treated 19 RE and 30
ICRB eyes with less advanced intraocular disease. All patients
survived and all treatable eyes were salvaged without the need for
external beam irradiation (the only eye lost was one that could not
be treated for technical reasons).
There are other ways to manage similar eyes. Some early staged
disease can be managed with laser photocoagulation alone with
success [12] but the conventional management for RE I-III was
primary external beam irradiation until the 1990’s.
Table 2. International Classification for Retinoblastoma (ICRB) Scheme.
International Classification for Intraocular Retinoblastoma (ICRB)
Group A Small intraretinal tumors away from foveola and disc
* All tumors are 3 mm or smaller in greatest dimension, confined to the retina and
* All tumors are located further than 3 mm from the foveola and 1.5 mm from the optic disc
Group B All remaining discrete tumors confined to the retina
* All other tumors confined to the retina not in Group A
* Tumor-associated subretinal fluid less than 3 mm from the tumor with no subretinal seeding
Group C Discrete Local disease with minimal subretinal or vitreous seeding
* Tumor(s) are discrete
* Subretinal fluid, present or past, without seeding involving up to J retina
* Local fine vitreous seeding may be present close to discrete tumor
* Local subretinal seeding less than 3 mm (2DD) from the tumor
Group D Diffuse disease with significant vitreous or subretinal seeding
* Tumor(s) may be massive or diffuse
* Subretinal fluid, present or past without seeding, involving up to total retinal detachment
* Diffuse or massive vitreous disease may include ‘‘greasy’’ seeds or avascular tumor masses
* Diffuse subretinal seeding may include subretinal plaques or tumor nodules
Group E Presence of any one or more of these poor prognosis features
* Tumor touching the lens
* Tumor anterior to anterior vitreous face involving ciliary body or anterior segment
* Diffuse infiltrating retinoblastoma
* Neovascular glaucoma
* Opaque media from hemorrhage
* Tumor necrosis with aseptic orbital cellulites
* Phthisis bulbi
doi:10.1371/journal.pone.0034120.t002
Table 3. Study patients.
Group I II III B C
Total No. Eyes 7 6 6 19 11
Age at Dx, months (range) 3.14 (1–7) 7.67 (1–16) 10.5 (2–28) 7.21 (1–28) 5.9 (0–16)
(Enucleation or EBR) 0 0 0 0 1*
Mean follow up, months 20.8 17.4 7.6 17 15.2
Median follow up, months 25 15 9 13.5 13
Range of follow up, months 7 to 27 6 to 31 3 to 10 5 to 31 6 to 33
*Eye enucleated after inability to repeat second IA treatment because of inability to cannulate the Ophthalmic artery.
Note: Because RE I, II and III have different definitions from ICRB B and C the numbers are not equivalent. The one ‘‘C’’ eye was RE Vb.
doi:10.1371/journal.pone.0034120.t003
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could be salvaged with radiation [13]. In the 1970’s success rates of
80% were reported [14]. In the 1980’s success rates of 83% were
reported [15]. In the 1990’s a success rate of 78.5% was reported
in Groups I and II [16]. The largest report specifically on RE I-III
treated with primary external beam irradiation was from our
group [17]. This paper is also the only one to report specifically on
radiation in RE I-III with information on ocular survival, need for
additional treatment and patient survival (from metastases and
second cancers). Overall, 85% of the eyes were salvaged though
53% needed additional treatments (such as laser or cryo). 4% of
patients died of metastatic retinoblastoma and Kaplan-Meier
estimates of second cancer incidence was 32% at 15 years.
Clinicians worldwide became progressively concerned about the
risk of second cancers following radiation therapy and in the mid
1990’s switched to multi-agent systemic chemotherapy as primary
treatment for retinoblastoma. More than 100 papers support the
success of this approach in eyes with limited disease [18].
Systemic chemotherapy (usually Carboplatin, Vincristine and
Etoposide) usually causes prompt reduction in size of intraocular
tumors but because sustained regression is rare supplemental focal
treatments with laser, cryotherapy, radioactive plaques and even
external beam irradiation are routinely employed [19]. For
Figure 1. Digital fundus images of three retinoblastoma eyes before (left panel) and after (right panel) ophthalmic artery
chemosurgery showing dramatic shrinkage of tumors without toxicity to the rest of the eye(s).
doi:10.1371/journal.pone.0034120.g001
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with chemotherapy alone and 23% did require subsequent
external beam irradiation to salvage the eye [20]. A recent report
from Korea emphasized that only 86% of REI-III eyes were
salvaged using multi-agent systemic chemotherapy and these
authors recommended 13 cycles of chemotherapy because of
persistent tumor viability [21]. They also emphasized their
concern about late re-growths in eyes treated with systemic
chemotherapy and the propensity for chemotherapy related
second malignancies.
Children with retinoblastoma have a high chance of long-term
survival so complications from treatment are more than academic.
As pointed out in an editorial in the Archives of Ophthalmology
the overwhelming majority of papers (.90%) on the use of
systemic chemotherapy (most written by ophthalmologists) for
retinoblastoma include no information about side effects [22]. For
those that report side effects complications such as the need for a
port, transfusion, fever and neutropenia are common as is
vincristine-related neurotoxicity [20]. Of further concern are
recent reports highlighting late ototoxicity (as a result of
carboplatin/cisplatin exposure) approaching 33% with carboplat-
in [23–25] and 100% with cisplatin [26]. Although all of the
children are too young to measure the impact on fertility, recent
articles have emphasized this potential toxicity of these drugs in
the pediatric cancer population and urged clinicians to find
alternatives [27].
Most distressing is the recognition that children with retino-
blastoma who receive chemotherapy (epipodophyllotoxins and
alkylating agents) are at risk for developing secondary leukemias
[28]. The true incidence is unknown but more than 20 such
children have been recognized worldwide. In addition, since some
(up to 24%) of children with RE I-III receiving systemic
chemotherapy will require subsequent external beam irradiation
the concern for radiation-related second cancers has not
disappeared with the use of primary systemic chemotherapy.
In conclusion, ophthalmic artery chemosurgery appears to be at
least (if not more) effective than prior published series of similar
eyes that were initially managed with primary radiation or
systemic chemotherapy and is associated with excellent patient
survival without the need for supplemental irradiation or the many
unfortunate side effects of systemic chemotherapy. Many eyes
achieve durable complete responses with single agent chemother-
apy alone. Long-term data will be needed to confirm these
encouraging findings.
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